Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X

InflaRx doses first patient in Phase II trial of IFX-1

Immunofluorescence staining pattern of ANCA. Credit: Simon Caulton.

Go Top